US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Release time：2024-05-22 02:50:52 Source：Stellar Signals news portal
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
- Previous：Harris accepts debate invite to face off with Trump's VP pick, which may come at convention
- Next：Sports betting roundup: Xander Schauffele's final putt pays off for bettors
Related articles
- Lafrenière continuing his breakthrough season as a solid contributor for Rangers in NHL playoffs
- Xinhua News
- Chinese, Australian FMs hold strategic dialogue
- 15 killed in road accident in central Ethiopia
- Jodie Turner
- China makes significant progress in geographical indication protection
- Tanzania to host field training for over 600 senior police officers from 14 African countries
- Interview: Somalia seeks drought relief funding in worst humanitarian crisis
- Harris accepts debate invite to face off with Trump's VP pick, which may come at convention
- Xi extends sympathy to Japanese PM over COVID
- Mark Wahlberg's new action
- China Focus: CPC Theoretical Study Motivates Party Members to Be Better Doers
- Thousands protest in Niger demanding withdrawal of U.S. troops
- China's space station lab module Mengtian ready for launch
- The government wants to buy their flood
- Interview: China's progress in environmental protection remarkable, says expert
- Kremlin calls Biden's remarks on Putin unacceptable
- New technologies of smart agriculture on display at 5th CIIE in Shanghai
- Mystery artist who erected signs comparing pothole
- Hungary ends row with EU over aid
Random recommendation
- Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Stellar Signals news portal sitemap